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Binding of non-catalytic ATP to human hexokinase I highlights
the structural components for enzyme–membrane association
control
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Garib Murshudov2, Marzia Bianchi4, Giordano Serafini4, Mauro Magnani4
and Martino Bolognesi1*
Background: Hexokinase I sets the pace of glycolysis in the brain, catalyzing
the ATP-dependent phosphorylation of glucose. The catalytic properties of
hexokinase I are dependent on product inhibition as well as on the action of
phosphate. In vivo, a large fraction of hexokinase I is bound to the mitochondrial
outer membrane, where the enzyme adopts a tetrameric assembly. The
mitochondrion-bound hexokinase I is believed to optimize the ATP/ADP
exchange between glucose phosphorylation and the mitochondrial oxidative
phosphorylation reactions.
Results: The crystal structure of human hexokinase I has been determined at
2.25 Å resolution. The overall structure of the enzyme is in keeping with the
closed conformation previously observed in yeast hexokinase. One molecule of
the ATP analogue AMP–PNP is bound to each N-terminal domain of the dimeric
enzyme in a surface cleft, showing specific interactions with the nucleotide, and
localized positive electrostatic potential. The molecular symmetry brings the two
bound AMP–PNP molecules, at the centre of two extended surface regions, to a
common side of the dimeric hexokinase I molecule.
Conclusions: The binding of AMP–PNP to a protein site separated from the
catalytic centre of human hexokinase I can be related to the role played by
some nucleotides in dissociating the enzyme from the mitochondrial membrane,
and helps in defining the molecular regions of hexokinase I that are expected to
be in contact with the mitochondrion. The structural information presented here
is in keeping with monoclonal antibody mapping of the free and mitochondrion-
bound forms of the enzyme, and with sequence analysis of hexokinases that
differ in their mitochondria binding properties.
Introduction
Hexokinase (ATP: D-hexose 6-phosphate transferase, EC
2.7.1.1) is the first enzyme in the glycolytic pathway and
catalyzes the ATP-based phosphorylation of glucose to
glucose-6-phosphate (G6P). In mammals four hexokinase
isozymes have been identified (named I–IV), which differ
in their catalytic and regulatory properties as well as in
their tissue localization. Hexokinases I, II and III (HK-I,
HK-II and HK-III, respectively) each have a similar mol-
ecular mass (approximately 100 kDa), whereas gluco-
kinase (hexokinase IV, HK-IV) is a single chain, 50 kDa
enzyme [1]. G6P, the reaction product, is a potent
inhibitor of HK-I and inorganic phosphate (Pi), at physio-
logical concentrations, can relieve this inhibition [1,2]. 
The crystal structures of the human and rat HK-I
isozymes (both approximately 100 kDa) and of Schistosoma
mansoni hexokinase (approximately 50 kDa) have been
reported recently [2–5], following the pioneering crystallo-
graphic analysis of yeast hexokinase (approximately
50 kDa) [6,7]. Human brain HK-I polypeptide chain is
composed of 917 amino acids [8], organized in two
domains that roughly encompass the N-terminal (residues
1–474) and the C-terminal halves (475–917) [2–4]. The
two domains display extensive sequence similarities
(approximately 70% amino acid identities; [9]). Moreover,
each domain is structurally related to yeast hexokinase,
supporting the view that mammalian hexokinases evolved
from a common ancestral enzyme, of approximately
50 kDa, by gene duplication and fusion [1,2,9,10]. 
Both human and rat HK-I are found to adopt a dimeric
structure in the crystalline state. Within the dimer, the
N-terminal domain from one subunit is juxtaposed to the
C-terminal domain of the second subunit, the molecular
symmetry of the dimer being close to, or exactly, a twofold
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axis [2–4]. The connection between the N- and C-terminal
domains of each subunit is provided by an extended
α helix, and their mutual interaction is mediated by a
limited number of intramolecular contacts (at Arg69,
Glu249, Asp251, Glu252, Leu797, Arg801, Cys813 and
Asp814). As shown for the single-domain yeast hexokinase
structure, one small and one large subdomain can be distin-
guished in the N- and C-terminal domains of HK-I. Upon
glucose binding, relative movements of the small and large
subdomains allow the enzyme to adopt the so-called
‘closed’ conformation [7,11].
Solution studies, controlled proteolysis and site-directed
mutagenesis, as well as recent crystallographic investiga-
tions, have shown that the catalytic action of HK-I is asso-
ciated with the C-terminal domain, which binds glucose
and the product G6P at distinct, neighboring, sites.
Product inhibition of the enzyme has been related to the
competition between ATP and G6P for a specific binding
site within the catalytic centre preventing glucose phos-
phorylation [12]. Alternatively, G6P could bind to the
N-terminal domain as an allosteric inhibitor, modulating
the catalytic activity through interdomain contacts
[5,12,13]. In both models, G6P inhibition is relieved by
binding of Pi at the N-terminal regulatory domain, result-
ing in either competition with G6P or allosteric modula-
tion of G6P binding to the C-terminal domain [4,12].
Mammalian HK-I is known to bind specifically and coop-
eratively, under physiological conditions, at pores of the
outer mitochondrial membrane, through an N-terminal
hydrophobic sequence (residues 1–11), which is inserted
into the lipid membrane space [14,15]. Association of the
enzyme with the contact sites between the outer and the
inner mitochondrial membranes promotes the formation
of hexokinase tetramers, which may assemble into a multi-
protein complex with porin, facilitating the ATP/ADP
traffic from/to the mitochondrial matrix, and eventually
from/to the oxidative phosphorylation cascade [16,17].
Moreover, mitochondrial outer membrane binding studies
on different molecular constructs of the mammalian
enzymes have shown that the isolated, catalytically active,
C-terminal domain is not capable of binding, as opposed
to the observed binding of the isolated N-terminal domain
[18]. Proteolytic cleavage of the N-terminal hydrophobic
segment 1–11, from the intact HK-I molecule or from the
isolated N-terminal domain, removes the enzyme–mem-
brane binding properties. On the other hand, it has been
shown that millimolar concentrations of nucleotide-
triphosphates, such as ATP, CTP, GTP and UTP, as well
as of pyrophosphate, favour hexokinase dissociation from
the outer mitochondrial membrane, an effect that can be
partially counterbalanced by Mg2+ [2–4,19]. Moreover,
G6P (at 0.2 mM levels) is able to affect the intracellular
distribution of the enzyme, promoting the release of the
mitochondria-bound forms [1,19,20]. The central role of
the enzyme N-terminal domain in mitochondrial mem-
brane association has been supported further by mapping
of the HK-I epitopes with monoclonal antibodies [21]. 
Such a structural and functional organization is believed to
be of physiological significance in regulation of the enzyme
activity and of the glycolytic flux in vivo. Similar mitochon-
dria association properties have been shown to be present
in the N-terminal domain of mammalian HK-II, but are
lacking for HK-III, which has been shown to be localized
at the nuclear periphery [1,18]. In this context, despite the
multiple functions displayed by ATP in hexokinase activ-
ity, it is remarkable that no crystal structures of hexoki-
nase–ATP complexes are yet available.
We have investigated the issue of HK-I membrane associ-
ation control through X-ray crystallography, analyzing
crystals of the human recombinant enzyme (in a truncated
form missing the N-terminal residues 1–11, tHK-I), grown
in the presence of the non-hydrolyzable ATP analogue
5′-adenylylimido-diphosphate (AMP–PNP), at 2.25 Å res-
olution. The results presented here show that AMP–PNP
binds at a previously unidentified surface cleft in each
N-terminal domain of the dimeric tHK-I. This region of
positive electrostatic potential is proposed to be a key
component of the hexokinase molecular interface to the
mitochondrial outer membrane.
Results and discussion
Structure determination and model quality
Solution of the crystal structure of tHK-I in a monoclinic
crystal form (space group P21), obtained in the presence of
the nucleotide analogue, glucose, G6P, and displaying one
tHK-I dimer per asymmetric unit, was achieved through
molecular replacement methods, using the AMoRe
program package from the CCP4 suite [22]. The atomic
coordinates of recombinant human hexokinase I, crystal-
lized in a different monoclinic crystal form in the presence
of glucose and G6P [2], were used as model for the mol-
ecular replacement analysis, providing unequivocal solu-
tions for both the rotational and the translational searches.
The resulting model was refined to 2.25 Å resolution,
against an X-ray diffraction data set collected at 100K at
the European Synchrotron Radiation Facility (Grenoble,
France), with final crystallographic R factor of 20.8%, and
Rfree of 27.9% (see the Materials and methods section).
During the crystallographic refinement, the bound glucose,
G6P and AMP–PNP molecules were promptly identified
as strong difference electron density features in both tHK-I
chains, but introduced only in the later stages (R factor
<25%), when they could be accurately modelled. The
refined tHK-1 dimer model consists of 1802 amino acid
residues, 4 glucose, 4 G6P, 6 Mg2+ ions, 459 water mol-
ecules, and 2 bound AMP–PNP moieties (Figure 1;
Table 1). Interpretable electron density is available for
chain A, starting from residue Thr12, whereas the first
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residue in density, for chain B, is Asp16. No electron
density is observed for residues Glu100–Gln103 (both
chains) and for residues Thr913–Glu914 (A chain). The
structure quality assessment together with relevant crystal-
lographic statistics is reported in Table 1; no residues are
observed out of the allowed Ramachandran regions [23].
The molecular assembly and fold
As previously described for recombinant human HK-I
[2–5] and for rat HK-I, each tHK-I chain is composed of
an N-terminal and a C-terminal domain, which reflect the
gene-duplication evolutionary origin of this hexokinase
isoform [1,10]. Accordingly, the two domains, which are
separated by a connection helix, have approximately the
same size (approximately 450 residues) and show compa-
rable folds (Figure 1), structurally related to the polypep-
tide fold observed in the approximately 50 kDa yeast and
Schistosoma mansoni hexokinases [5–7]. Moreover, because
of the presence of glucose in the crystallization buffer and
in the crystallized enzyme, both the N- and C-terminal
domains adopt a closed conformation, which is held to
shape the active site properly, favouring ATP→glucose
phosphoryl transfer, during the catalytic cycle [24,25]. A
structural overlay of the Cα backbones of the core
residues in the N- and C-terminal domains of tHK-I yields
a root mean square deviation (rmsd) of 1.14 Å (calculated
using 232 Cα atom pairs).
Each tHK-I subunit is related to its asymmetric unit mate
by an almost exact twofold axis, which is oriented parallel to
the unit-cell face defined by the b and c axes, forming an
angle of about 35° with respect to the c direction. The loca-
tion of the molecular twofold axis juxtaposes the N-termi-
nal domain of the A subunit next to the C-terminal domain
of the B subunit (Figure 1). In accordance with such highly
symmetric assembly of the tHK-I dimer, in a trigonal crystal
form of human HK-I (space group P3221), crystallized in
the presence of glucose and Pi only, the molecular twofold
axis of the dimeric enzyme is coincident with a crystallo-
graphic dyad [3]. The total subunit interface area that is
shielded from solvent (1.4 Å radius probe), upon formation
of the tHK-I dimer, is 2014 Å2. The packing of tHK-I
dimers in the crystal lattice does not shed light, however, on
models for additional quaternary structure aggregation in a
tetrameric form of the enzyme. In this respect it has been
noticed previously that tetramer formation is correlated
with binding of HK-I to mitochondria [4,16].
The optimal overlay of the full Cα backbones of tHK-I
subunits A against B yields an rmsd of 0.51 Å (calculated
using 892 Cα atom pairs). This value is comparable with
the rmsd calculated for each individual subunit, and for the
full tHK-I dimer, with respect to the molecular replace-
ment search model that was refined at 2.8 Å resolution
(rmsd 0.85 Å, 0.75 Å, and 0.96 Å, respectively). All the pre-
ceding figures indicate the absence of significant quater-
nary and tertiary structure rearrangements between crystal
forms of human (t)HK-I, obtained in the presence of satu-
rating glucose and G6P concentrations, although influence
of crystal contacts on the dynamics of the enzyme mol-
ecule (as displayed by the atomic thermal parameters) has
been reported [4]. In view of such a structural conserva-
tion, no further discussion is devoted here to a description
of tHK-I general structure assembly [2–5]. In this context
it should nevertheless be mentioned that a total of four
(structural) cation binding sites have been recognized at
structurally equivalent loops located at the N- and C-termi-
nal domain interface of each chain (loops 241–253 and
691–703), as previously reported for human HK-I [3].
Because of electrostatic compensation of neighbouring
residues, and the presence of 200 mM MgSO4 in the crys-
tallization buffer, the bound cations have been modelled as
full occupancy Mg2+ ions (displaying refined B factors of
41.7 Å2, 56.0 Å2, 28.8 Å2, 35.7 Å2, in the N- and in the
C-terminal domains of chains A and B, respectively).
Glucose- and G6P-binding sites
In relation to the relatively high crystallographic resolution
achieved, the tHK-I model presented here allows a clear
characterization of the glucose- and G6P-binding sites,
observed in the N- and C-terminal domains (Figure 2;
Table 2). In particular, as indicated by unequivocal 
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Figure 1
The tHK-I dimer. Stereoview Cα trace of the
tHK-I dimer showing the two N termini, chains
A and B (in cyan and red, respectively) and
the location of the AMP–PNP-binding site in
the N-terminal domains (both lower in the
figure). The bound AMP–PNP molecules are
shown in green. The molecular twofold axis is
roughly vertical in the page. (Drawn with
MOLSCRIPT [50].)
N
C
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Structure
difference electron-density peaks in the final stages of the
refinement, the glucose molecule, which had been initially
modelled in the β-anomer configuration, is indeed present
as the α-anomer in all four domains of the tHK-I dimer.
Such an observation is supported further by inspection of
atomic B factors, which refine to values 50% higher than
those of the neighbouring atoms, when the glucose O1 atom
is refined in the β position. Moreover, all the four glucose
molecules (which have been refined with a constant occu-
pancy of 1.0) show similar average B factors (33.6 Å2,
34.9 Å2, 31.7 Å2 and 28.9 Å2, in the N- and C-terminal
domains of chains A and B, respectively), indicating that the
glucose binding processes occur with comparable efficiency
at the different domains, under the tHK-I crystal growth
conditions. The presence of the glucose α-anomer is unex-
pected because previous crystallographic reports suggested
either the presence of the β-anomer (for human HK-I) or of
both the α- and β-anomers (for rat HK-I) [1,26,27].
The glucose molecule is fully solvent inaccessible,
within the protein core, in both tHK-I domains. Despite
the presence of the α-anomer, the glucopyranose ring
provides substrate–protein interactions which are, in
general, in line with the hydrogen bonding and van der
Waals contacts scheme proposed for human [2], for rat
HK-I [5] and for yeast HK [1,7], with additional interac-
tions occurring at the O5 glucose atom. On the other
hand, comparison of the hydrogen-bonding assignments
for tHK-I (Table 2) with those reported for human and
for rat HK-I [2,5] shows that partial modification of the
ligand-binding interactions can be recognized at the
G6P-binding sites of tHK-I. In this respect, inspection of
the atomic B factors and of residual electron density
shows that G6P is present as the β-anomer and does not
suggest different product occupancies in the four
binding sites present in the asymmetric unit, nor alterna-
tive binding modes, as previously proposed [2]. The
observation of partly modified protein–ligand interac-
tions at both N-and C-terminal domains for both glucose
and G6P, as compared with the other mammalian hexo-
kinase structures previously reported, might be related, in
general, to a slight contraction of the protein molecule at
100K, might result from the selection of the α-D-glucose
anomer, but might also reflect a more accurate electron-
density fitting, related to improvements in the crystallo-
graphic resolution achieved for tHK-I. 
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Table 1
Crystallographic data and refinement statistics.
Space group P21
Unit cell a = 82.4 Å
b = 174.3 Å
c = 86.3 Å
β = 90.5°
Total number of reflections (35–2.25 Å) 405,442
Unique reflections 118,575
Rmerge (%) 5.0
I/σ(I) 8.0
I/σ(I) (2.3–2.25 Å resolution shell) 6.8
Reflections used in refinement (10.0–2.25 Å) 95,087
Reflections in Rfree calculation (5%) 4994
Completeness (10.0–2.25 Å) 87.0%
Completeness last shell (2.29–2.25 Å) 74.7%
R factor 0.208
Rfree 0.279
Number of protein atoms 14,097
Number of atoms in ligated species 174
Number of solvent atoms 459 H2O, 6 Mg2+
Rms deviations (Å)
bonds 0.012
angles 0.037
planes 0.039
Average B factor values (Å2)
Protein 
mainchain 40.5
sidechain 43.0
overall 41.7
Glucose & G6P 35.6
AMP–PNP 
adenine (chain A/chain B) 47.6/39.6
ribose (chain A/chain B) 49.4/46.2
phosphate tail (chain A/chain B) 81.9/77.1
Solvent 45.3
Overall coordinate ESU based on R value (Å)
(Cruickshanks DPI) 0.32
Overall coordinate ESU based on Rfree value (Å) 0.26
Figure 2
Glucose-binding site. A view of the electron density observed for the
glucose and G6P molecules in the tHK-I C-terminal domain binding
site (chain A). The electron density is contoured at 1.0σ level.
Additional residues involved in substrate/product recognition are also
displayed (for further details see Table 2).
A comparison between the glucose-binding sites in the
N-and C-terminal domains (of both chains A and B)
shows, within the limits of the coordinate experimental
error, a striking conservation of structure, residues and
enzyme–glucose interactions at the two sites (Table 2).
Similarly, comparison of the G6P-binding sites (N-termi-
nal against C-terminal domain) shows that the two sites
differ by the replacement of two residues only. Thr863
substitutes for the N-terminal domain residue Ser415,
maintaining, however, two hydrogen bonds to the G6P
atom O7* (the asterisk is used to identify oxygen atoms
from the 6-phosphate group). On the other hand, residues
Ser89 and Asn537, which fall next to the G6P molecule in
the N- and C-terminal domains, respectively, do not
display direct hydrogen bonding with the ligand. It is
therefore difficult to envisage different binding affinities
for glucose and for G6P [28–30], in the N- and C-terminal
domains, respectively, based exclusively on the static
structure of the tHK-I bound form reported here. 
The non-catalytic ATP-binding site
The crystal structure analysis of rat HK-I has shown that
the N-terminal residues (1–11), which are mainly respon-
sible for mitochondrial membrane anchoring of the
enzyme, adopt a helical structure, proposed to be protrud-
ing from the enzyme surface in order to provide efficient
interaction with the phospholipid bilayer and porin [4,5].
As a result of the symmetric assembly of the A against B
subunits, the two N-terminal residues in the dimeric
enzyme (residue 12 in tHK-I chain A and residue 16 in
chain B) are located approximately 115 Å apart. The
protein surface comprised between the two N termini in
the assembled dimer shows two distinct, virtually identical
zones, which appear as roughly planar and are defined by
the 16–34, 365–400, 422–436 helices and by residues
30–31 and 344–347. The two regions, each covering about
650 Å2, have an orientation that is approximately perpen-
dicular to the molecular twofold axis (Figures 1,3c,4). 
Inspection of difference electron-density maps, during the
crystallographic refinement of tHK-I has constantly shown
strong positive density features at a site located approxi-
mately at the centre of each of these two surface regions.
The observed electron density, in the N-domains of both
A and B subunits, is compatible with a bound AMP–PNP
molecule (Figure 3; Table 3), which is hosted in a surface
cleft defined by helices 16–29, 32–52 (and the connecting
30–31 residues), 335–344, 365–400, 422–436 and by the
344–347 loop. The adenine ring is accommodated at the
dead end of the cleft, in stacking interaction with residues
Arg30 and Phe380, and in van der Waals contact (<4.0 Å)
with residues Thr376 and Ile377. The adenine ring is
solvent accessible for 67 Å2, its N6 atom being hydrogen
bonded to Leu31 O (3.4 Å) and to Asn384 OD1 (3.4 Å)
atoms. The AMP–PNP ribose ring is in van der Waals
contact with residues Thr376 and Phe380, and is solvent
accessible for 80 Å2. The ribose O2′ atom is hydrogen
bonded to the Arg30 NH2 atom (2.9 Å), and possibly also
to the His373 NE2 atom (3.5 Å). The three residues
Asp23, Arg30 and His373 form a sort of tight triad, stabi-
lized by mutual hydrogen bonds and electrostatic interac-
tions, which can help in shaping the pocket for productive
interaction with the adenosine moiety of the nucleotide.
In fact, stacking between the adenine ring and Arg30
guanidino group appears to be instrumental to orientate
the arginine sidechain and exploit its hydrogen bonding
capability to the ribose O2′ atom [31]. In the absence of
the AMP–PNP molecule, in human HK-I [2], the Arg30
guanidino group is shifted away from the position
observed in the presence of the nucleotide. It might also
be noted that the ribose O4′ atom is at 3.2 Å from both
CD2 and CE2 atoms of Phe380, of which the aromatic
ring is seen edge on from the ribose. Such an orientation is
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Table 2
Hydrogen-bond interactions (≤ 3.4 Å) observed at the glucose-
and G6P-binding sites in the N- and the C-terminal domains of
tHK-I (chain A).
N-terminal domain Distance C-terminal domain Distance
atoms (Å) atoms (Å)
Glucose atoms
O1 Glu294 OE2 2.4 Glu742 OE1 2.7
Wat273 3.1 Wat457 3.1
O2 Thr172 OG1 3.1 Thr620 OG1 2.9
Glu260 OE1 3.0 Glu708 OE1 3.1
O3 Asn208 ND2 2.8 Asn656 OD1 2.9
Glu260 OE2 2.6 Glu708 OD1 2.7
O4 Asp209 OD1 2.6 Asn656 OD1 3.2
Asn235 OD1 3.3 Asp657 OD1 2.7
– – Asn683 ND2 3.0
O5 Lys173 NZ 3.2 Lys621 NZ 3.0
O6 Lys173 NZ 2.8 Lys621 NZ 3.2
Asp209 OD2 2.5 Asp657 OD2 2.7
Wat206 3.0 Wat164 2.9
G6P atoms
O1 Asp209 OD2 2.5 Ser603 OG 3.3
– – Asp657 OD2 2.5
– – Wat246 2.6
O2 Asp84 OD1 2.7 Asp532 OD1 2.7
Asp84 OD2 3.1 Ser897 OG 2.9
Ser449 OG 3.2 Wat246 3.2
O3 Asp84 OD2 3.0 Asp532 OD2 3.0
Ser449 N 3.2 Ser897 OG 3.3
– – Ser897 N 3.1
O4 Asp413 OD2 2.6 Asp861 OD2 2.7
Wat89 2.9 – –
O7* Ser415 N 3.0 Thr63 N 2.7
Ser415 OG 2.5 Thr863 OG1 2.7
Wat89 3.1 – –
O8* Thr232 N 2.4 Thr680 N 3.0
Thr232 OG1 2.8 Thr680 OG1 3.1
Wat79 2.9 Wat164 2.7
O9* Ser88 N 2.7 Thr536 N 2.9
Ser88 OG 2.8 Thr536 OG1 3.1
– – Wat382 2.6
*Identifies oxygen atoms from the 6-phosphate group.
strongly suggestive of the presence of a bifurcated hydro-
gen bond involving the ribose O4′ atom and the two aro-
matic protons from Phe380 [32], as an additional
contribution to the shaping/stabilization of the adenine-
binding pocket.
The phosphate groups of the nucleotide are increasingly
exposed to solvent, in the order α → γ, and find electrosta-
tic compensation and hydrogen-bond donors in residues
Arg425, Arg426 and Lys429 (Table 3; Figure 3). The
triphosphate tails adopt slightly different conformations in
the two tHK-I chains.
The average temperature factors of the bound
nucleotides (which were refined with full occupancy) are
lower for the adenine rings (48 Å2, 40 Å2, for subunits A
and B, respectively) and for ribose (49 Å2 and 46 Å2,
respectively), reflecting the temperature factors of the
neighbouring protein residues, whereas they are higher
for the phosphate groups (averages for the triphosphate
tails are 82 Å2 and 77 Å2). Such an atomic B factor
increase along the nucleotide molecule can be inter-
preted as the result of increased flexibility, being in fact
related to the varying levels of solvent exposure and
protein–AMP–PNP interactions observed. 
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Figure 3
Recognition of AMP–PNP at the tHK-I non-
catalytic nucleotide binding site. (a) Stereoview
of the electron density observed for the
AMP–PNP molecule bound to tHK-I subunit A.
(b) Stereoview of the AMP–PNP-binding site,
shown together with part of the helical
segments and the residues that define the
binding site and stabilize the bound nucleotide.
(c) GRASP [51] view of the AMP–PNP-binding
site in the N-terminal domain of subunit B.
Negative electrostatic potential (<–7 kT/e) is
red, positive (>7 kT/e) is blue.
His373
Asp23
Arg30
N terminus
Arg425
His373
Asp23
Arg30
N termimus
Arg425
(a)
(b)
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Structure
In both tHK-I chains a strong electron density feature is
observed next to the nucleotide β- and γ-phosphate
groups, at distances of 2.5–3.2 Å from the phosphate
oxygen atoms, although with slightly different interactions
in the two chains. In consideration of the crystallization
buffer composition, these electron-density peaks could be
interpreted as Mg2+ ions (the crystallographic refinement
of which, at full occupancy, yields B factors of approxi-
mately 70 Å2). Alternatively, in view of their solvent
exposed location, such electron density features might rep-
resent alternative conformations for the nucleotide triphos-
phate tail, or a different tightly bound solvent species.
A structural overlay of the tHK-I structure, in the presence
of the nucleotide, with that of nucleotide-free human HK-I,
focussed on the region of AMP–PNP binding, shows a
substantial conservation of the protein structure (rmsd
over 88 Cα is 0.4 Å), a conservation that essentially
extends to the sidechain conformations of residues build-
ing up the adenine–ribose pocket, with the exception of
Arg30. Thus, AMP–PNP binding does not appear to
require significant structural adaptation on the enzyme
side, nor do structural rearrangements seem to be trans-
mitted from the AMP–PNP-binding site (in the N-termi-
nal domain) to the enzyme active site, which is 82 Å away
(in the C-terminal domain).
Inspection of the tHK-I refined structure in the surface
region surrounding the AMP–PNP-binding site shows a
notable distribution of 17 positively charged residues, five of
which are involved in direct protein–AMP–PNP interaction
(Table 3; Figure 4). Such a structural localization of posi-
tively charged residues surrounding the nucleotide binding
site, all belonging to the N-terminal domain, supports the
hypothesis of a membrane interface location for this mol-
ecular region, which would stabilize the interaction between
HK-I and the mitochondrion through the establishment of
ionic interactions with the membrane phospholipid phos-
phate heads. Indeed, binding of the enzyme is influenced
by the phospholipidic composition of the membrane [33].
It has been shown previously that triphosphate nucleotides
favour HK-I dissociation from the membrane, an effect that
can be partly reversed by the addition of Mg2+ [19,34–36].
The model presented here shows that AMP–PNP binding
to tHK-I occurs at an N-terminal domain site, the structural
features of which are those of a nucleotide-recognition
pocket endowed with broad specificity. Indeed, a very
simple modelling approach shows that such a site can easily
accommodate di- or tri-phosphate nucleotides other than
ATP. The simultaneous exposure of their negatively
charged tri- or di-phosphate tails to the mitochondrial
membrane interface would decrease the amount of
protein–membrane electrostatic attraction, promoting
enzyme solubilization. A similar HK-I membrane dissocia-
tion effect can also be induced by the addition of pyrophos-
phate, but not of phosphate, which might be too small to
bind effectively at the proposed non-catalytic nucleotide
site. On the contrary, the addition of Mg2+ would partly
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Figure 4
Electrostatic residues around the non-catalytic
nucleotide binding site. A stereoview of the
tHK-I surface that hosts the AMP–PNP-
binding site in chain B, drawn approximately
edge on (rotated about 90° with respect to
Figure 3c). The AMP–PNP molecule (green)
is displayed together with the positively
charged residues (blue) which are proposed
to favour outer mitochondrial membrane
association (also see Figure 5).
N terminus N terminus Structure
Table 3
Hydrogen-bond interactions observed at AMP–PNP-binding
sites in A and B chains of tHK-I.
AMP–PNP A chain Distance B chain Distance
atom residue (Å) residue (Å)
N1 – – Wat70 2.9
N6 Leu31 O 3.4 Leu31 O (3.5)
Asn384 OD1 3.4 Asn384 OD1 3.4
O2′ Arg30 NH2 2.9 Arg30 NH2 (3.5)
His373 NE2 (3.5) His373 NE2 3.2
O3′ – – His373 NE2 3.2
O5′ Arg426 NH2 2.8 – –
O1A* Arg425 NH1 2.5 – –
Arg425 NH2 2.8 – –
O2A* – – Arg425 NH1 3.2
– – Arg425 NH2 3.1
– – Arg426 NE 2.8
O3A* Arg425 NH1 (3.5) – –
O1B* Arg426 NH1 2.7 Lys429 2.4
N3B* Arg425 NH2 (3.5) – –
O3G* Asn345 ND2 3.2 – –
′Oxygen atoms from the ribose ring. *Atoms from the triphosphate group.
compensate for the electrostatic repulsion resulting from
nucleotide binding to the enzyme, antagonizing, as previ-
ously observed [34], the nucleotide tri-phosphate solubi-
lization effects. It should be noticed, in this respect, that
potential Mg2+-binding sites have been located on the
phosphate tails of both AMP–PNP molecules in the tHK-I
structure reported here.
In agreement with the above mechanistic hypotheses, the
recombinant N-terminal tHK-I domain (residues 12–454)
was found to be able to bind to RED A columns (Amicon
Corp, Lexington). This affinity column support displays
negative groups and is used commonly for the purification
of nucleotide binding enzymes [37]. Remarkably, the
N-terminal tHK-I domain was selectively eluted by 2 mM
ATP, but not by 2 mM Mg-ATP nor by 1.5 mM G6P
(M Magnani and G Serafini, unpublished observations).
The above structural results and model for HK-I–mem-
brane interaction is furthermore consistent with monoclonal
antibody mapping experiments, conducted on the intact rat
HK-I molecule, which have shown that: firstly, outer mito-
chondrial membrane binding can be fully ascribed to the
N-terminal half of the enzyme; and secondly, additional
interactions, besides those related to the N-terminal
anchoring helix, promote the HK-I (or HK-II) membrane
association. Particularly, in a combination of monoclonal
antibody protection experiments, sequence analysis and
antibody recognition of the mitochondrially bound enzyme,
it was shown that HK-I segments 1–9, 36–60, and 365–385,
all physically located in the N-terminal ‘large subdomain’,
are primarily involved in enzyme–outer mitochondrial
membrane contacts [18,21]. Remarkably, these protein seg-
ments match, within the spatial resolution allowed by anti-
body mapping, the region observed around the
non-catalytic ATP-binding site in the crystal structure of
the tHK-I–AMP–PNP complex (Figures 3,4). Incidentally,
we note that specific localization of HK-I at the mitochon-
drial membrane contact sites might be driven by association
of a yet unidentified membrane (or porin) bound species to
the N-terminal domain non-catalytic nucleotide-binding
cleft, a locating process which is exploited by different
membrane associated protein systems [38].
As discussed above, the AMP–PNP molecule makes exten-
sive interactions with the tHK-I protein matrix, a feature
observed in several unrelated ATP-dependent proteins and
recognized as an essential requirement for productive ATP
recognition [39,40]. Remarkably, despite the absence of
secondary structure homologies, the non-catalytic ATP-
binding site in tHK-I provides cofactor recognition through
a network of interactions that are topologically and chemi-
cally reminiscent of those observed in cAMP-dependent
protein kinase and in D-Ala–D-Ala ligase, in which ATP
plays a catalytic role [39]. Such an observation is in keeping
with the view that proteins with unrelated folds can host
similar localized structural features in order to satisfy ATP
recognition. In this context, however, tHK-I represents a
unique case, in that it displays two different ATP-binding
sites (in two separate domains) meeting the requirements
of catalysis and of regulation of mitochondrial membrane
association, respectively.
An additional argument for discussion, in this context,
concerns the structural/evolutionary divergence of the pro-
posed non-catalytic ATP-binding site, observed in the
tHK-I N-terminal domain, as compared with the homolo-
gous region in the C-terminal domain, which does not
bind to mitochondria as an isolated domain. A superposi-
tion of the non-catalytic ATP-binding site, observed in the
tHK-I N-terminal domain, with the structurally homolo-
gous region from the C-terminal domain shows the substi-
tution of three charged residues (Arg426, Lys429 and
Arg433) with neutral or negatively charged residues
(Ile874, Gln877 and Glu881, respectively; see Figure 5).
Moreover, the Phe380→Arg828 substitution might affect
the polarity of the adenine-binding cleft and the location
of Arg30, whereas the presence of Gly824 (substituting for
Thr376) might influence the binding mode of the incom-
ing nucleotide ribose ring.
From a more general viewpoint, Figure 5 shows a struc-
ture-based comparison of amino acid residues from the
tHK-I non-catalytic ATP-binding region versus struc-
turally equivalent residues from the N- and C-terminal
domains of other hexokinase enzymes, of which the
mitochondrial membrane binding behaviours are known.
Such a comparison allows one to recognize the following
general properties. HK-I N-terminal domains display
full conservation of the residues involved in recognition
of the nucleotide analogue, including Arg30 and Phe380,
which provide stacking interaction with the adenine
ring. Moreover, the charged surface residues that are
expected to provide electrostatic interaction with the
mitochondrial membrane, on the basis of the present
crystallographic model, are fully conserved in human and
rat HK-I enzymes. HK-II enzymes, which are also
known to bind at the mitochondrial membrane, show the
least amino acid variation from this trend in their N-ter-
minal domains. On the other hand, such a pattern is defi-
nitely altered (with loss or inversion of electrostatic
charges) in the C-terminal domains of HK-I and HK-II,
in both domains of HK-III, in glucokinase and in the
enzymes from S. mansoni and yeast (Figure 5). Remark-
ably, non-conservative substitution of the non-catalytic
ATP-binding site residues and perturbation of the elec-
trostatics-linked residues is constantly observed in the
hexokinase domains that are not capable of outer mito-
chondrial membrane binding. 
A final issue concerns the solubilization effects that are
induced on the mitochondrially bound HK-I by the action
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of G6P. In this respect it should be considered that the rat
and human HK-I have been crystallized under different
growth conditions, in the presence of at least 1 mM G6P, in
the presence/absence of AMP–PNP (this work and [2,5]).
As discussed above, all these crystal structures show that
the product is bound to both N- and C-terminal domains, at
a protein internal location, next to the glucose-binding site.
Moreover, even at 10 mM G6P levels, a concentration 50-
fold higher than that required for HK-I solubilization from
the mitochondrial membrane [19], no enzyme surface loca-
tion, including the AMP–PNP site identified here, displays
electron density compatible with a bound G6P molecule. 
Although it cannot be excluded that the closed-dimeric
form of HK-I reported in the crystalline state reflects only
an inhibited-latent enzyme structure, the above observa-
tions might indicate that the G6P effects on HK-I solubi-
lization are indirect, as compared with those proposed here
for tri- and di-nucleotide action. In particular, G6P-induced
solubilization might occur as a result of a perturbation of
the HK-I tetramer formation process at the mitochondrial
membrane [16]. Indeed, dissociation of tetrameric HK-I
might be promoted by a G6P-induced conformational shift
towards the closed form. Alternatively, G6P might promote
HK-I solubilization by binding to a mitochondrial mem-
brane component, tightly associated with HK-I at the
membrane contact sites. Such an hypothesis is consistent
with the above reported observation that tHK-I is not
eluted from RED A columns by 1.5 mM G6P (M Magnani
and G Serafini, unpublished observations), and with the
known species dependence of the G6P-induced HK-I sol-
ubilization. Indeed, it is known that although rat HK-I can
be almost completely released from mitochondria by the
action of G6P, only 20% of the human brain enzyme can be
solubilized under similar conditions [20].
Biological implications
Hexokinase catalyzes the ATP-dependent phosphoryla-
tion of glucose to glucose-6-phosphate (G6P), the entry
point of glucose into glycolysis. Sequence and functional
data indicate that for two mammalian hexokinase
isozymes (HK-I and HK-III, both approximately
100 kDa) the catalytic activity is associated with the 
C-terminal half of the molecule, whereas the N-terminal
domain has regulatory properties. HK-I activity is inhib-
ited by the enzymatic reaction product, G6P; binding of
Pi to the enzyme N-terminal domain relieves G6P inhibi-
tion. The details and structural bases of both processes,
which include transmission of allosteric signals between
the two domains, at least in the case of Pi activation, and
competition with catalytic ATP binding to the active site,
are still widely debated.
At least for HK-I and HK-II, the N-terminal domain
promotes association to the outer mitochondrial mem-
brane contact sites. In fact, approximately 70% of
human brain HK-I is bound to mitochondria, presum-
ably in a tetrameric form, in association with mitochon-
drial porin (a voltage-dependent anion channel). Such
structural organization has been proposed to allow pref-
erential diffusion of ATP (produced by mitochondrial
oxidative phosphorylation) to the HK-I catalytic centre,
providing at the same time the mitochondrial space with
a constant flux of ADP, as a result of HK-I catalyzed
glucose phosphorylation. Given that the rate of the two
processes (glucose phosphorylation by HK-I and
intramitochondrial oxidative phosphorylation) correlate,
HK-I might act as a coordinator enzyme, preventing an
imbalance of glycolytic reactions over mitochondrial
oxidative reactions, which could lead to the accumula-
tion of (neurotoxic) lactate. In an excess of ATP, HK-I
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Figure 5
Evolutionary conservation of residues around
the non-catalytic ATP binding site. The tHK-I
amino acid residues that are proposed to be
involved in tHK-I membrane binding (on the
basis of the present crystallographic
investigation) are compared with structurally
equivalent residues from the N-terminal
domains of different hexokinase molecules
that are known to bind to the mitochondrial
membrane (N-terminal domains of rat HK-I,
and human and rat HK-II), with the domains of
hexokinase molecules that do not bind to the
mitochondrial membrane (N-terminal domains
of human and rat HK-III, glucokinase; all
C-terminal domains) and with the hexokinase
molecules from S. mansoni and from yeast.
Residue sites that are directly involved in
AMP–PNP binding are indicated by bold
numbers (see also Figure 4; amino acid
numbering refers to tHK-I sequence).
HK-I    N terminus    K K D K R H N K H H F N R R R R H K R R R   Human
HK-I    N terminus    K K D K R Q D K Q H F N S R R R H K R R R   Rat
HK-II   N terminus    Q K D Q R N E K R R T S R R K R H K R R R   Human
HK-II   N terminus    Q K D Q R N D K E R T S R R K R H K R R R   Rat
HK-I    C terminus    R Q E E H T D R L T R Q R N R I H Q K E S   Human
HK-I    C terminus    R A Q K K H D C L E R Q N K K V H E R D S   Rat
HK-II   C terminus    R A Q K Q H D C L E R Q A K K V H E K D S   Human
HK-II   C terminus    R A Q K K H D C L E R Q N K K V H E R D S   Rat
HK-III  N terminus    E T Q E K P P S A H T Q T Q S V Q G M L S   Human
HK-III  N terminus    S E Q E K P P A A R T Q T H C I K E M L S   Rat
HK-III  C terminus    R L E E R R D S R E Q Q E A S L A A R E T   Human
HK-III  C terminus    R I E E Q C D S R E R Q E T R L S V R K T   Rat
HK-IV                 T L E Q Q Q D T K R T H V R E R H A R R T   Human
HK-IV                 T L E Q Q Q D S K R T H V R E R H A R R T   Rat
HK                    E K V V D K D P Y Y K Y R E E R T D D K R   S. mansoni
HK                    D E H Q T E D P E R T R A D L R I Y T G T   Yeast
Structure
20 21 23 24 30 223 345 346 350 373 380 384 405 407 425 426 428 429 432 433 441
dissociates from the mitochondria with a reported reduc-
tion of its catalytic efficiency. Regulation of the cytoplas-
mic glycolytic flux would then be achieved only through
the G6P (product) inhibition mechanisms.
Binding of HK-I to mitochondria is dependent on the
insertion of an 11-residue N-terminal helical segment
into the phospholipid bilayer. This property has been ele-
gantly transferred to unrelated proteins by grafting this
segment to their N termini. Antibody protection experi-
ments and construction of hybrid molecules incorporat-
ing different hexokinase domains, however, show that
other HK-I regions, located in the N-terminal ‘large
subdomain’, participate in the process of membrane
association. Binding of hexokinase to the outer mito-
chondrial membrane is tissue specific and developmen-
tally regulated, the enzyme activity being markedly
elevated in several cancer cells.
The crystal structure of recombinant human HK-I, in
complex with glucose, G6P and with the nonhydrolyz-
able ATP analogue 5′-adenylylimido diphosphate, allows
us to locate a protein surface cleft that displays the char-
acteristics of a broad specificity nucleotide-binding site.
In the dimeric HK-I, the two nucleotide-binding sites are
related by a molecular twofold axis and fall at the centre
of two wide molecular regions, rich in positively charged
residues, which can face simultaneously an approaching
mitochondrial membrane. Thus, in the absence of bound
ATP and in addition to the known insertion of the N-ter-
minal helix in the phospholipid bilayer, electrostatic
interactions can help secure the enzyme to the mem-
brane phospholipidic heads. On the basis of the three-
dimensional structure reported in this paper, the tHK-I
solubilization effects (with respect to mitochondria)
related to the addition of ATP, nucleotides and
pyrophosphate, as well as the contrasting role played by
Mg2+ ions, might be explained by the perturbation of
such enzyme–membrane electrostatic interactions.
Materials and methods
Expression and purification
The tHK-I gene was expressed as recombinant enzyme in BL21(DE3)
Escherichia coli cells, using the pET system, inducible with IPTG. Details
about optimization of human recombinant HK-I expression in bacteria are
reported by Bianchi et al. [41]. Next, tHK-I was purified to homogeneity fol-
lowing the purification procedure used for the full-length recombinant
enzyme [42], with the only exception that the elution buffer for the Blue A
column contained 40 mM potassium chloride (KCl) instead of 90 mM KCl.
Crystallization
An extensive search for suitable crystal growth conditions was carried
over using sparse matrix crystallization kits (Hampton Research, Laguna
Hills, CA). After refinement of the physico-chemical parameters, crystals
with dimensions often exceeding 0.3 × 0.2 × 0.1 mm3 were obtained, in
the hanging-drop geometry at 4°C using a 700 µl reservoir solution con-
taining 15% (w/v) PEG 8K, 200 mM magnesium acetate, 100 mM
sodium acetate, 10% (v/v) glycerol, 3 mM β-mercaptoethanol, pH 5.5.
The 6 µl droplet used contained 4 µl of protein solution (15 mg/ml in
diluted buffer, 10 mM glucose, 3 mM β-mercaptoethanol, 9% (v/v)
glycerol, 40 mM KCl, 1.5 mM G6P), 1 µl of reservoir medium and 1 µl of
60 mM AMP–PNP in water [43].
Data collection and reduction
Diffraction data were firstly collected in-house and subsequently using
synchrotron radiation at the ID14 beamline, European Synchrotron
Radiation Facility (λ = 0.936 Å). Crystal were cryo-frozen at 100K
using a modified mother liquor solution that contained all the protein
droplet components and 15% (v/v) glycerol, as cryoprotectant. A
single crystal was used to collect the 2.25 Å resolution diffracted inten-
sities, which were processed and reduced using the programs XDISP,
DENZO and SCALEPACK of the HKL package [44]. The tHK-I crystals
belong to the monoclinic P21 space group with unit cell constants
a = 82.4 Å, b = 174.3 Å, c = 86.3 Å, β = 90.5° and contain one dimer
per asymmetric unit. A summary of the data collection and reduction
statistics is given in Table 1.
Structure determination and refinement
The structure of tHK-I was determined by molecular replacement
methods using the program AMoRe [22] of the CCP4 suite. Rotational
searches in the 12.0–5.0 Å resolution range were carried over using the
atomic coordinates of a previously determined human hexokinase
(PDB code 1hkb) as the search model. Two peaks with correlation
values of 14.9 (11σ) and 13.5 (10σ), respectively, were promptly found.
The third rotation function peak had a correlation coefficient of 9.5.
Translational searches were carried out in an iterative manner in the
12.0–5.5 Å resolution range, yielding two solutions with correlation coef-
ficients of 34.0 and 33.7 respectively; the corresponding R factor was
47.1% (12.0–5.5 Å resolution range). Subsequently, rigid-body refine-
ment of the two solutions at 4.5 Å resolution yielded a R factor value of
37.7% (correlation coefficient of 65.5). Further rigid-body refinement of
the two tHK-I chains, each divided into two independent domains
(N- and C-terminal), did not provide any significant protein readjustment.
A random set of reflections (5%) was flagged for Rfree calculation and
several cycles of simulated annealing/slow cooling were performed
using the X-PLOR package [45], with R factor drop to 29.9%
(Rfree = 35.2%) in the 8.0–3.5 Å resolution range. The model obtained
was then subjected to 237 cycles of maximum likelihood refinement
using REFMAC [46] and including bulk solvent correction. The macro-
molecular model was continuously inspected against difference Fourier
maps and corrections made accordingly [47]. Solvent molecules were
located at stereochemically acceptable sites. The final model (R factor
20.8%, Rfree 27.9%, for all reflections observed in the 10.0–2.25 Å reso-
lution range) conforms quite satisfactorily to the accepted statistics for
protein stereochemical parameters [23,48] (Table 1). 
Accession numbers
Atomic coordinates for tHK-I and structure factors have been
deposited with the Protein Data Bank [49] as dataset 1qha.
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